Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. ovarian cell
Show results for
Products
Applications

Companies

News
Articles

Refine by
Date

  • Older

Ovarian Cell Articles & Analysis

8 news found

MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

” At data cutoff (July 16, 2022), 51 of 52 patients enrolled in the Phase 2 expansion phase of the trial had received at least one dose of tulmimetostat in the following cohorts: metastatic castration-resistant prostate cancer, lymphoma, BAP1-mutated mesothelioma, ARID1A-mutated ovarian clear cell carcinoma, ARID1A-mutated endometrial carcinoma and ...

ByMorphoSys AG


SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments

SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments

” SEngine’s PARIS® test grows a patient’s tumor cells in a lab, then analyzes them to determine the safest and most effective medications. ...

BySEngine Precision Medicine


Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear cell carcinoma (OCCC) treated with immune checkpoint inhibitors lived significantly longer (had ...

ByLIXTE Biotechnology Holdings, Inc.


SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers

SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers

SEngine’s drug screening of patient-derived tumor avatar models, generated by the Dana-Farber CPDM and stored as live tumor cells are essential to patients accessing modern functional precision medicine assays and personalized drug information. ...

BySEngine Precision Medicine


PARIS Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer

PARIS Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer

The patient’s oncologist, Heidi Gray, MD, who specializes in ovarian cancer at the University of Washington, ordered the PARIS® Test. ...

BySEngine Precision Medicine


SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting

SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting

Details related to the poster presentation are as follows: Title: A cancer organogram test as a guide for oncology treatments in solid tumors: an analysis of 628 tests in 419 patients First Author: Astrid Margossian, MD, PhD Senior Author: Carla Grandori, MD, PhD Abstract Number: 2602 Poster Session: Developmental Therapeutics— Immunotherapy About PARIS® Test The PARIS® ...

BySEngine Precision Medicine


SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer

SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer

The poster presentation highlighted the utility of the PARIS® Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in ovarian cancer. In an ovarian cancer cohort of 44 evaluable patient samples, authors found that: Ovarian cancer patient-derived 3D cultures preserve the histopathological and ...

BySEngine Precision Medicine


Adult Stem Cells

Adult Stem Cells

Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, which multiply by cell division to replenish dying cells and regenerate damaged tissue. ...

ByAelan Cell Technologies

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT